Digest Network Come funziona
Network
/
Società
Un
Non verificato

United Therapeutics Corporation

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaMedicina - VarieSalute

56 comunicati stampa

Guarda tutti i comunicati
29/04/2026
Mercato del lavoro
Scienza
Cardiologia
Biotecnologia
Medicina alternativa
Oncologia
Salute
Sanità
United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
Fonte
United Therapeutics Corporation
Emittente
Business Wire
1.00
0
22/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Scienza
Cardiologia
Biotecnologia
Medicina - Varie
Sanità
Salute
United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
Fonte
United Therapeutics Corporation
Emittente
Business Wire
1.00
0
20/04/2026
Scienza
Medicina - Varie
Cardiologia
Biotecnologia
Salute
Farmaceutica
Eventi
Industria
United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
Fonte
United Therapeutics Corporation
Emittente
Business Wire
1.00
0
08/04/2026
Industria
Biotecnologia
Farmaceutica
Salute
Cardiologia
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
Fonte
United Therapeutics Corporation
Emittente
Business Wire
1.00
0
30/03/2026
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Biotecnologia
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
Fonte
United Therapeutics Corporation
Emittente
Business Wire
1.00
0
11/03/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Cardiologia
United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
Fonte
United Therapeutics Corporation
Emittente
Business Wire
1.00
0
09/03/2026
Finanza
Biotecnologia
Farmaceutica
Salute
Cardiologia
United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
Fonte
United Therapeutics Corporation
Emittente
Business Wire
1.00
0
03/03/2026
Web e Social Network
Eventi
Finanza
Biotecnologia
Sanità
Salute
Farmaceutica
Cardiologia
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
Fonte
United Therapeutics Corporation
Emittente
Business Wire
1.00
0
02/03/2026
Web e Social Network
Industria
Analisi di mercato
Scienza
Medicina - Varie
Cardiologia
Sanità
Biotecnologia
Farmaceutica
Salute
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
Fonte
United Therapeutics Corporation
Emittente
Business Wire
1.00
0
25/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Sanità
Salute
Farmaceutica
Cardiologia
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
Fonte
United Therapeutics Corporation
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0